
AI in drug discovery: Separating hype from reality, and what it holds for CROs
Dr Kenneth Barr, Senior Vice President, Discovery Services at Syngene International, examines the reality of using AI in drug discovery and its relevance for CROs. In an industry where investments are huge, the time to market is over a decade, and success rates hover around 10%, technological advances that significantly… Read More














